Cancer Therapy

Discovery of novel anticancer drugs inhibiting Plk1 reported

Published in Cancer Weekly, December 16th, 2003

Cyclacel Limited, the U.K.-based biopharmaceutical company, announced that it discovered a series of novel, potent, and highly selective drugs inhibiting human Polo-like kinase 1 (Plk1).

Plk1 plays a central role in the regulation of the cancer cell cycle at the stage of mitosis or cell division. David Glover, chief scientist of Cyclacel's Polgen division, first discovered Plk in 1988. The Plk1 inhibitors were discovered using Cyclacel's state-of-the-art rational drug design technology.

Spiro Rombotis, CEO of Cyclacel said, "The Plk1 inhibitors are the latest additions to our growing pipeline of cell cycle modulators, which includes clinical,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry